Legal Representation
Attorney
Steven A. Abreu
USPTO Deadlines
Next Deadline
1620 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-12-19)
Due Date
December 19, 2029
Grace Period Ends
June 19, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 6, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Dec 19, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Dec 19, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Nov 17, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Nov 16, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Oct 31, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Oct 30, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Oct 30, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Aug 23, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 23, 2023 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Aug 23, 2023 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN |
| Aug 10, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Aug 7, 2023 | IUAF | S | USE AMENDMENT FILED |
| Aug 7, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Feb 9, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 8, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Feb 8, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jan 23, 2023 | EXT5 | S | SOU EXTENSION 5 FILED |
| Jan 23, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 12, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jul 8, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Jul 8, 2022 | EXT4 | S | SOU EXTENSION 4 FILED |
| Jul 8, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 17, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 15, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Feb 15, 2022 | EXT3 | S | SOU EXTENSION 3 FILED |
| Feb 15, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 5, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 3, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Aug 3, 2021 | EXT2 | S | SOU EXTENSION 2 FILED |
| Aug 3, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 12, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 10, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Feb 10, 2021 | EXT1 | S | SOU EXTENSION 1 FILED |
| Feb 10, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 18, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jun 23, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jun 23, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jun 3, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| May 19, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 19, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| May 19, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| May 19, 2020 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| May 19, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| May 19, 2020 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| May 14, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 13, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| May 13, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| May 13, 2020 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| May 13, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
Detailed Classifications
Class 005
House mark for pharmaceutical and medical preparations containing biomedical compounds, namely, peptides, stapled peptides, and synthetic peptides, all comprised of amino acids for the medical treatment of cancer, inflammatory conditions, immunological disorders, cardiovascular conditions, infectious diseases, and neurological conditions; biomedical compounds for medical purposes, namely, miniproteins and cell-penetrating miniproteins (CPMPs) arrays for diagnosing cancer, inflammatory conditions, immunological disorders, cardiovascular conditions, infectious diseases, and neurological conditions
First Use Anywhere:
May 22, 2023
First Use in Commerce:
May 22, 2023
Additional Information
Pseudo Mark
FOG PHARMA
Classification
International Classes
005
USPTO Documents
Click to view cached USPTO documents for this trademark
Only administrators can request new documents from USPTO